Meridian Bioscience (NASDAQ: VIVO) released its earnings data on Wednesday. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.19 by $0.01. The company had revenue of $45.40 million for the quarter, compared to the consensus estimate of $44.34 million.
A number of analysts have recently weighed in on VIVO shares. Analysts at Robert W. Baird raised their price target on shares of Meridian Bioscience from $22.00 to $24.00 in a research note to investors on Monday, December 17th. They now have an ?outperform? rating on the stock. On a related note, analysts at Cowen reiterated an ?outperform? rating on shares of Meridian Bioscience in a research note to investors on Thursday, November 29th. Finally, analysts at Wedbush downgraded shares of Meridian Bioscience from a ?neutral? rating to an ?underperform? rating in a research note to investors on Wednesday, November 28th. They now have a $17.00 price target on the stock.
Three analysts have rated the stock with a buy rating, one has given an overweight rating, six have issued a hold rating, and two have issued a sell rating to the company. Meridian Bioscience presently has a consensus rating of ?hold? and an average price target of $20.43.
Shares of Meridian Bioscience (VIVO) opened at 21.47 on Wednesday. Meridian Bioscience (VIVO) has a 52 week low of $16.19 and a 52 week high of $21.56. The stock?s 50-day moving average is currently $20.56. The company has a market cap of $886.4 million and a P/E ratio of 26.84.
Meridian Bioscience, Inc. (Meridian) is a fully-integrated life science company. The Company is engaged in the developing, manufacturing, selling and distribution of diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.